It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

PET and CT Radiation Therapy Study for Stage III Non-Small Cell Lung Cancer

Clinical Trial Title: 
Randomized phase II trial of individualized adaptive radiotherapy using during-treatment FDG-PET/CT and modern technology in locally advanced non-small cell lung cancer (NSCLC).
Clinical Trial Protocol ID: 
16021603
Clinical Trial Investigator Name: 
Gaurav Marwaha, MD
Clinical Trial Protocol Description: 

This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high-energy X-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans, to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor and cause less damage to healthy tissue.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have FDG-avid (maximum SUV >= 4.0) (from PET scan of any date, any scanner) and histologically or cytologically proven non-small cell lung cancer.
  • Have a CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless medically contraindicated) within 6 weeks prior to registration.
  • Have a history/physical examination, including documentation of weight, within 2 weeks prior to registration.
  • Are able to tolerate PET/CT imaging.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 942-0836
Contact Name: 
Adrianne Kajmowicz, RN, BSN